Tiziana Life Sciences Ltd
TLSA1.710USD
-0.090-5.00%
Horário de mercado （ET）Cotações atrasadas em 15 min
203.19MValor de mercado
--P/L TTM
Mais detalhes de Tiziana Life Sciences Ltd Empresa
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that is specialized in the developing transformative therapies for neurodegenerative and neuroinflammatory. The Company’s clinical pipeline includes drug assets for secondary progressive multiple sclerosis, Alzheimer’s, and ALS. Its lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer’s and other CNS indications. Its Anti IL-6R mAb (TZLS-501), a fully human mAb binds to both membrane-bound and soluble forms of IL-6R, an inflammatory cytokine driving chronic inflammation associated with autoimmune disease and cancer, reducing circulating levels of the IL-6 cytokine.
Informações de Tiziana Life Sciences Ltd
Código da empresaTLSA
Nome da EmpresaTiziana Life Sciences Ltd
Data de listagemNov 20, 2018
CEOMr. Ivor Elrifi
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 20
Endereço3rd Floor, 11-12 St. James's Square
CidadeLONDON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited Kingdom
Código postalSW1Y 4LB
Telefone442074952379
Sitehttps://www.tizianalifesciences.com/
Código da empresaTLSA
Data de listagemNov 20, 2018
CEOMr. Ivor Elrifi
Executivos da empresa Tiziana Life Sciences Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Non-Executive Independent Director
Non-Executive Independent Director
8.25K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ivor Elrifi
Mr. Ivor Elrifi
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. William A. Clementi, Pharm.D.
Dr. William A. Clementi, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Non-Executive Independent Director
Non-Executive Independent Director
8.25K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Ivor Elrifi
Mr. Ivor Elrifi
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
--
--
Dr. William A. Clementi, Pharm.D.
Dr. William A. Clementi, Pharm.D.
Chief Development Officer
Chief Development Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qui, 30 de out
Atualizado em: qui, 30 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Cerrone (Gabriele M)
35.38%
Monica Fonda (Natalia Laura)
5.73%
Chernett (Jorey)
5.01%
Dauntless Investment Group, LLC
2.88%
Citadel Advisors LLC
0.17%
Outro
50.84%
Investidores
Investidores
Proporção
Cerrone (Gabriele M)
35.38%
Monica Fonda (Natalia Laura)
5.73%
Chernett (Jorey)
5.01%
Dauntless Investment Group, LLC
2.88%
Citadel Advisors LLC
0.17%
Outro
50.84%
Tipos de investidores
Investidores
Proporção
Individual Investor
46.12%
Investment Advisor
3.36%
Investment Advisor/Hedge Fund
0.25%
Hedge Fund
0.18%
Research Firm
0.10%
Outro
49.98%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
67
4.64M
3.91%
+430.59K
2025Q2
68
51.10M
45.84%
+9.72M
2025Q1
69
45.10M
40.46%
+3.34M
2024Q4
64
40.33M
36.45%
-5.07M
2024Q3
58
41.30M
37.43%
-3.04M
2024Q2
51
40.27M
36.45%
-4.04M
2024Q1
48
40.16M
36.35%
-4.27M
2023Q4
52
45.25M
44.24%
+1.19M
2023Q3
58
45.24M
44.24%
+1.10M
2023Q2
54
45.32M
44.32%
+1.19M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Cerrone (Gabriele M)
42.04M
35.38%
+2.70M
+6.85%
Mar 31, 2025
Chernett (Jorey)
5.95M
5.01%
+5.95M
--
Jun 11, 2025
Dauntless Investment Group, LLC
3.42M
2.88%
+1.68M
+96.52%
Jun 30, 2025
Citadel Advisors LLC
198.99K
0.17%
+198.99K
--
Jun 30, 2025
HSBC Global Asset Management (UK) Limited
105.36K
0.09%
--
--
Jun 30, 2025
Zhang Financial LLC
89.76K
0.08%
-6.50K
-6.75%
Jun 30, 2025
Susquehanna International Group, LLP
86.08K
0.07%
+28.75K
+50.16%
Jun 30, 2025
HRT Financial LP
84.11K
0.07%
+13.74K
+19.53%
Jun 30, 2025
Kovitz Investment Group Partners, LLC
79.36K
0.07%
--
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: qui, 6 de nov
Atualizado em: qui, 6 de nov
Nome
Proporção
Fidelity Nasdaq Composite Index ETF
0%
Fidelity Nasdaq Composite Index ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Jul 16, 2020
Split
1→2.5
Data
Tipo
Proporção
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Oct 20, 2021
Merger
2→1
Jul 16, 2020
Split
1→2.5
